|
rs759435862
|
|
|
0.020 |
GeneticVariation |
BEFREE |
No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas.
|
27039821 |
2016 |
|
rs759412116
|
|
|
0.010 |
GeneticVariation |
BEFREE |
XRCC1 Arg399Gln showed a borderline significant association with adenocarcinoma (adjusted OR 1.89, 95%CI 1.00-3.57, p=0.051).
|
21198260 |
2010 |
|
rs755683317
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
|
rs754332870
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Analysis of the KRAS gene showed only a G12C variation in one large cell carcinoma (LCC) patient, whereas variants were not found in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) cases.
|
30048458 |
2018 |
|
rs754332870
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Seven of 17 cases (41%) were reclassified in the adenocarcinoma with solid pattern group, which showed one KRAS G12C and one EGFR E709K + G719C double mutation in addition to mutations in TP53.
|
26430808 |
2016 |
|
rs753152604
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Firstly, lentivirus-mediated transduction of KRAS(G12V), MYC and human papillomavirus 16 (HPV16) E6/E7 under the control of a tetracyclin-inducible promoter efficiently immortalized and transformed primary HPDECs, which gave rise to adenocarcinomas subcutaneously in an immune-deficient mouse xenograft model, depending on expression of the four genes.
|
24858378 |
2014 |
|
rs752021744
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Similar to H460 tumors, PD-0325901 as single agent or in combination with PF-04691502 significantly inhibited growth of tumor lesions in lungs in Kras(G12D-LSL) mice when treatment started at adenocarcinoma stage (at 14 weeks post-Adeno-Cre inhalation).
|
22684718 |
2012 |
|
rs751144688
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In particular, CEACAM5 , TACSTD1 , S100P , and MSLN have shown to be upregulated in adenocarcinoma, and increased expression levels of CEACAM5 and TACSTD1 were significantly correlated with poorer patient outcomes.
|
18182341 |
2007 |
|
rs750749
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Pooled evaluation of cases from the two aforementioned studies suggested differences in the distribution of susceptibility alleles by histology; adenocarcinoma cases were more likely to be carriers of the susceptibility alleles for SNP rs9370729 (p-trend=0.02) and SNP rs750749 (p-trend=0.09).
|
19446866 |
2009 |
|
rs746702110
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The associations between the OGG1 Cys/Cys genotype and adenocarcinoma risk and between XRCC1 Arg194Trp polymorphism and lung cancer risk among heavy smokers remained robust given prior probabilities of 25% (FPRP = 0.238) and 10% (FPRP = 0.276), respectively.
|
15840879 |
2005 |
|
rs746284240
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mice with pancreas-specific tsTAg expression developed acinar cell dysplasia by 22 weeks without PanIN formation, while mice expressing both tsTAg and Kras(G12D) developed highly aggressive adenocarcinoma with a ductal cell phenotype within a short period, and died within 3 weeks.
|
25042889 |
2014 |
|
rs736775
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PF-based chemotherapy significantly decreased risk of death for patients carrying GPx3 rs736775 TC/CC and age ≤ 60 years or with diffused type adenocarcinoma compared to surgery alone.
|
30114685 |
2018 |
|
rs7309332
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified by tumor histology, the association between the GLUT3 rs7309332C>T and OS/DFS was not limited to either squamous cell carcinoma (SCC) or adenocarcinoma (AC), although the significant association remained only in AC for OS (P = 0.40 for SCC and P = 0.04 for OS) and only in SCC for DFS (P = 0.03 for SCC and P = 0.08 for OS).
|
30954677 |
2019 |
|
rs7015700
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TNKS1 SNPs (rs11991621 rs10503380, and rs7015700) were associated with NSCLC risk, whereas rs6601328 and rs12541709 inversely associated with NSCLC or ADC risk in this Chinese population.
|
26617760 |
2015 |
|
rs689465
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs689465 AA genotype was significantly associated with longer overall survival (OS) (13.0 months vs 8.8 months, P = 0.019 for log-rank test; hazard ratio [HR] 0.624; 95% confidence internal [CI] 0.418-0.931) and progression-free survival (5.3 months vs 4.0 months, P = 0.018 for log-rank test; HR 0.627; 95% CI 0.421-0.934) compared with AG or GG genotype, especially in patients with adenocarcinoma (P = 0.002), performance status of 1 (P = 0.009) and stage IV disease (P = 0.012), and treated with gemcitabine-based chemotherapy (P = 0.012).
|
25131817 |
2016 |
|
rs6601328
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TNKS1 SNPs (rs11991621 rs10503380, and rs7015700) were associated with NSCLC risk, whereas rs6601328 and rs12541709 inversely associated with NSCLC or ADC risk in this Chinese population.
|
26617760 |
2015 |
|
rs6495309
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An association between the rs6495309C > T polymorphism and survival outcome was demonstrated in smokers and never-smokers, and in squamous-cell carcinomas and adenocarcinomas.
|
22722785 |
2012 |
|
rs6465657
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We determined that levels of LMTK2 transcripts in prostate adenocarcinomas were only 32% of those in benign tissues (p = 3.2 x 10(-7)), and that an independent effect of genotype at variant rs6465657 on LMTK2 expression in benign (n = 39) and malignant tissues (n = 21) was also evident (P = 0.002).
|
20569440 |
2010 |
|
rs61748181
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
rs587782289
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An SNP, Thr706Ala, in the POLI gene encoding another translesion DNA polymerase was associated with adenocarcinoma and squamous cell carcinoma risk, particularly in individuals of ages < 61 years (OR Ala/Ala + Ala/Thr vs. Thr/Thr = 1.5 and 2.4, respectively).
|
15609317 |
2005 |
|
rs586339
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Non-small-cell lung cancer (NSCLC) patients with adenocarcinoma histology who were homozygous for KDM4A single nucleotide polymorphism (SNP)-A482 (rs586339) were recently shown to have significantly worse overall survival (OS) compared with patients with the wild-type or the heterozygous genotype at this locus (hazard ratio=1.68, P=0.042).
|
28059867 |
2017 |
|
rs577715207
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A common set of genes dysregulated in lung cancer was obtained, including BPA1, DUSP6, ASCL1, RNAS1 and S100P. p63 and CK 5/6 p63 are useful for differentiating adenocarcinoma and small cell lung cancer from squamous cell carcinoma.
|
20332665 |
2010 |
|
rs577715207
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A commercially available monoclonal antibody against S100P</span> stained 78% of 300 urothelial carcinomas while only 2% of 256 prostatic adenocarcinomas</span> and none of 137 renal cell carcinomas stained.
|
17460449 |
2007 |
|
rs542027040
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One eccrine gland adenocarcinoma showed allelic loss of 17p and a Cys 176 Arg mutation in the p53 gene.
|
10660129 |
2000 |
|
rs505922
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNP rs505922, located within the first intron of the ABO gene, has been associated with the adenocarcinoma subtype of pancreatic cancer.
|
22642827 |
2012 |